We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-20.78%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$664M
AUM Growth
-$172M
Cap. Flow
+$85.8M
Cap. Flow %
12.92%
Top 10 Hldgs %
40.96%
Holding
86
New
4
Increased
14
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$22.2M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$17.1M
3
NKTR icon
Nektar Therapeutics
NKTR
+$15.8M
4
KA
Kineta, Inc. Common Stock
KA
+$13.6M
5
NVRO
NEVRO CORP.
NVRO
+$13M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$52.7M
2
BPMC
Blueprint Medicines
BPMC
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 86.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
51
DELISTED
Aptose Biosciences, Inc.
APTO
$3.18M 0.48%
2,404
– –
KITE
52
DELISTED
Kite Pharma, Inc.
KITE
$3.16M 0.48%
68,800
– –
BCRX icon
53
BioCryst Pharmaceuticals
BCRX
$2.24B
$3.06M 0.46%
1,080,000
– –
SNDX icon
54
Syndax Pharmaceuticals
SNDX
$1.7B
$2.86M 0.43%
+214,419
New +$2.7M
ATRA icon
55
Atara Biotherapeutics
ATRA
$77M
$2.85M 0.43%
6,000
– –
CFRX
56
DELISTED
ContraFect Corporation
CFRX
$2.84M 0.43%
1,043
+750
+256% +$2.12M
BLCM
57
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.81M 0.42%
30,000
– –
IOVA icon
58
Iovance Biotherapeutics
IOVA
$1.93B
$2.54M 0.38%
499,815
– –
IMDZ
59
DELISTED
Immune Design Corp.
IMDZ
$2.46M 0.37%
189,000
– –
EPRS
60
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$2.41M 0.36%
896,600
– –
TPST icon
61
Tempest Therapeutics
TPST
$14M
$2.39M 0.36%
86
– –
CRIS icon
62
Curis
CRIS
$10M
$1.87M 0.28%
581
– –
RGNX icon
63
Regenxbio
RGNX
$638M
$1.69M 0.26%
156,741
– –
CBIO
64
Crescent Biopharma
CBIO
$552M
$1.69M 0.25%
2,836
– –
NGNE icon
65
Neurogene
NGNE
$656M
$1.32M 0.2%
7,500
– –
BITI
66
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$1.32M 0.2%
50,000
– –
FOLD
67
DELISTED
Amicus Therapeutics
FOLD
$1.27M 0.19%
150,000
– –
ASND icon
68
Ascendis Pharma A/S
ASND
$16B
$1.14M 0.17%
61,500
– –
AVEO
69
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1M 0.15%
108,772
– –
GNVC
70
DELISTED
GenVec, Inc.
GNVC
$948K 0.14%
117,624
– –
PVCT
71
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$836K 0.13%
2,200,000
– –
VCYT icon
72
Veracyte
VCYT
$3.61B
$745K 0.11%
137,990
– –
NSTG
73
DELISTED
NanoString Technologies, Inc.
NSTG
$609K 0.09%
40,000
– –
HTGM
74
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$577K 0.09%
1,117
– –
NEOS
75
DELISTED
Neos Therapeutics, Inc
NEOS
$540K 0.08%
50,000
– –
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cormorant Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Cormorant Asset Management held 86 positions worth $664M, down 21% from $836M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management deployed $85.8M of net new capital in Q1 2016, opening 4 new positions and adding to 14 existing holdings. Its largest new stake was Kineta, Inc. Common Stock: 12,333 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier.

On the sell side, the most notable exit was DYAX CORPORATION, an estimated $52.7M sold.

  • Cormorant Asset Management's largest Q1 2016 buy was Kineta, Inc. Common Stock: 12,333 shares worth $16.6M.
  • Cormorant Asset Management added most to Sage Therapeutics in Q1 2016, an estimated $22.2M increase.
  • Cormorant Asset Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $52.7M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $664M portfolio in Q1 2016.
  • Cormorant Asset Management opened 4 new positions and closed 2 in Q1 2016.
  • Cormorant Asset Management's portfolio value fell 21% quarter-over-quarter to $664M.

Based on Cormorant Asset Management's 13F filing for Q1 2016, filed 16 May 2016.